-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Y-mAbs Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2023.
- Y-mAbs Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$7M, a 9.67% increase year-over-year.
- Y-mAbs Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$23.9M, a 23.8% decline year-over-year.
- Y-mAbs Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.4M, a 77.6% increase from 2022.
- Y-mAbs Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$95.6M, a 72.9% decline from 2021.
- Y-mAbs Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$55.3M, a 53.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)